Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients.
Peker Eyüboğlu İ, Koca S, Çelik B, Güllü Amuran G, Uğurlu MÜ, Alan Ö, Akın Telli T, Yumuk PF, Akkiprik M. Peker Eyüboğlu İ, et al. Among authors: alan o. Int J Breast Cancer. 2024 Nov 14;2024:6117394. doi: 10.1155/2024/6117394. eCollection 2024. Int J Breast Cancer. 2024. PMID: 39574517 Free PMC article.
A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin-paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study.
Gürler F, Tay F, Sucuoğlu İşleyen Z, Yerlikaya T, Hendem E, Esen SA, Sütçüoğlu O, Işık D, Niğdelioğlu B, Özen M, Şahin E, Şakalar T, Şengül Samancı N, Alan Ö, Hacıbekiroğlu İ, Algın E, Yılmaz MK, Türk HM, Öksüzoğlu B, Yavuz A, Yüksel O, Bora H, Yazıcı O, Özet A, Özdemir N. Gürler F, et al. Among authors: alan o. Cancer Med. 2024 Jul;13(14):e70002. doi: 10.1002/cam4.70002. Cancer Med. 2024. PMID: 39030808 Free PMC article.
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Yildirim S, Dogan A, Akdag G, Yüksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Alan O, Coban Kokten S, Isik D, Surmeli H, Basoglu T, Sever ON, Odabas H, Yildirim ME, Turan N. Yildirim S, et al. Among authors: alan o. Sci Rep. 2024 May 27;14(1):12123. doi: 10.1038/s41598-024-63096-7. Sci Rep. 2024. PMID: 38802494 Free PMC article.
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A, Guven DC, Koksal B, Karaoglan BB, Kivrak D, Ismayilov R, Aslan F, Sutcuoglu O, Yazici O, Kadioglu A, Alan O, Majidova N, Erciyestepe M, Ozcan E, Akdag G, Taban H, Kaya AO, Guliyev M, Yildirim N, Sakalar T, Yazilitas D, Unal C, On S, Biter S, Demirci NS, Senler FC, Kemal Y, Halil OD, Gullu I, Aksoy S. Akyildiz A, et al. Among authors: alan o. Eur Arch Otorhinolaryngol. 2024 Sep;281(9):4991-4999. doi: 10.1007/s00405-024-08744-4. Epub 2024 May 25. Eur Arch Otorhinolaryngol. 2024. PMID: 38795147 Free PMC article.
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
Akdag G, Yildirim S, Dogan A, Yuksel Yasar Z, Bal H, Kinikoglu O, Oksuz S, Ozkerim U, Tunbekici S, Yildiz HS, Turkoglu E, Alan O, Coban Kokten S, Isik D, Sever ON, Odabas H, Yildirim ME, Turan N. Akdag G, et al. Among authors: alan o. Chemotherapy. 2024;69(3):141-149. doi: 10.1159/000537874. Epub 2024 Feb 16. Chemotherapy. 2024. PMID: 38368871
60 results